-
VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach Prostate (IF 2.8) Pub Date : 2024-03-18 Hendrik Heers, Oliver Chwilka, Johannes Huber, Claus Vogelmeier, Andreas Rembert Koczulla, Jörg Ingo Baumbach, Tobias Boeselt
Many diseases leave behind specific metabolites which can be detected from breath and urine as volatile organic compounds (VOC). Our group previously described VOC-based methods for the detection of bladder cancer and urinary tract infections. This study investigated whether prostate cancer can be diagnosed from VOCs in urine headspace.
-
Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease Prostate (IF 2.8) Pub Date : 2024-03-13 Felipe M. Berg, Eduardo T. O. Correia, Eric C. Abenojar, James P. Basilion, Thomas J. Rosol, Ronaldo H. Baroni, Agata A. Exner, Leonardo K. Bittencourt
BackgroundThere is an increasing interest in using preclinical models for development and assessment of medical devices and imaging techniques for prostatic disease care. Still, a comprehensive assessment of the prostate's radiological anatomy in primary preclinical models such as dogs, rabbits, and mice utilizing human anatomy as a reference point remains necessary with no optimal model for each purpose
-
A west African ancestry‐associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening Prostate (IF 2.8) Pub Date : 2024-03-13 Jian Gu, Lisly Chery, Graciela M. Nogueras González, Chad Huff, Sara Strom, Jeffrey A. Jones, Donald P. Griffith, Steven E. Canfield, Xuemei Wang, Xuelin Huang, Pamela Roberson, Qing H. Meng, Patricia Troncoso, Michael Ittmann, Michael Covinsky, Michael Scheurer, Margarita Irizarry Ramirez, Curtis A. Pettaway
BackgroundAfrican American (AA) men have the highest incidence and mortality rates of prostate cancer (PCa) among all racial groups in the United States. While race is a social construct, for AA men, this overlaps with west African ancestry. Many of the PCa susceptibility variants exhibit distinct allele frequencies and risk estimates across different races and contribute substantially to the large
-
Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era Prostate (IF 2.8) Pub Date : 2024-03-13 Sean A. Fletcher, Mufaddal M. Mamawala, Albert E. Holler, Yasin Bhanji, Katarzyna J. Macura, Claire M. de la Calle, Christian P. Pavlovich
BackgroundTo validate the use of a cumulative cancer locations (CCLO) score, a measurement of tumor volume on biopsy, and to develop a novel magnetic resonance imaging (MRI)‐informed CCLO (mCCLO) score to predict clinical outcomes on active surveillance (AS).MethodsThe CCLO score is a sum of uniquely involved sextants with prostate cancer on diagnostic + confirmatory biopsy. The mCCLO score incorporates
-
Defining the challenges and opportunities for using patient‐derived models in prostate cancer research Prostate (IF 2.8) Pub Date : 2024-03-07 W. Nathaniel Brennen, Clémentine Le Magnen, Sofia Karkampouna, Nicolas Anselmino, Nathalie Bock, Nicholas Choo, Ashlee K. Clark, Ilsa M. Coleman, Robin Dolgos, Alison M. Ferguson, David L. Goode, Marianna Krutihof‐de Julio, Nora M. Navone, Peter S. Nelson, Edward O'Neill, Laura H. Porter, Weranja Ranasinghe, Takuro Sunada, Elizabeth D. Williams, Lisa M. Butler, Eva Corey, Wytske M. van Weerden, Renea
BackgroundThere are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect the diversity of disease seen in clinical practice. In response to this challenge, research laboratories around the world have been developing new patient‐derived models of prostate cancer, including
-
Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system Prostate (IF 2.8) Pub Date : 2024-03-07 Richard Bennett, Eric V. Li, Austin Y. Ho, Jonathan A. Aguiar, Clayton Neill, Steven P. Rowe, Hiten D. Patel, Hatice Savas, Ashley E. Ross
IntroductionThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides appropriate use criteria (AUC) for prostate‐specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) which include guidance on imaging in newly diagnosed prostate cancer and in patients with biochemically recurrent (BCR) disease. This study aims to examine trends in PSMA implementation
-
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway Prostate (IF 2.8) Pub Date : 2024-03-06 Xiaoliang Hua, Jiong Zhang, Juan Chen, Rui Feng, Li Zhang, Xianguo Chen, Qing Jiang, Cheng Yang, Chaozhao Liang
BackgroundChronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great
-
Preanalytical stability of molecular forms of prostate‐specific antigen in serum samples (PSA, free PSA, [−2]proPSA) and their impact on fPSA/tPSA ratio and PHI Prostate (IF 2.8) Pub Date : 2024-02-28 Václav Šimánek, Radana Vrzáková, Roman Viták, Michal Jirásko, Tomáš Fürst, Ondřej Topolčan, Ladislav Pecen, Vladimír Vurm, Radek Kučera
BackgroundProstate cancer is a common cancer in men. Detection methods include the measurement of biomarkers: prostate‐specific antigen (PSA), free PSA, [−2]proPSA, and the calculated indices: fPSA/tPSA ratio and Prostate Health Index (PHI). Proper preanalytical conditions are crucial for precise measurement and failure to adhere to protocols or regulations can influence the diagnostic algorithm. We
-
Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix Prostate (IF 2.8) Pub Date : 2024-02-28 Shuhei Kamada, Shinichi Sakamoto, Ryo Kinoshita, Xue Zhao, Tomohiko Kamasako, Ryosuke Yamase, Rii Junryo, Shinpei Saito, Pae Sangjon, Akinori Takei, Yasutaka Yamada, Yusuke Goto, Yusuke Imamura, Taro Iguchi, Atsushi Mizokami, Hiroyoshi Suzuki, Koichiro Akakura, Tomohiko Ichikawa
BackgroundTo clarify the clinical roles of changes in testosterone (T) levels with a cut‐off level of 20 ng/dL as predictive factors for prostate cancer patients treated with degarelix acetate.MethodsA total of 120 prostate cancer patients who received hormone therapies with gonadotropin‐releasing hormone antagonist degarelix acetate were retrospectively analyzed. The predictive values of nadir T levels
-
Cancer cells employ lipid droplets to survive toxic stress Prostate (IF 2.8) Pub Date : 2024-02-27 Laurie G. Kostecka, Sabrina Mendez, Melvin Li, Pratik Khare, Cissy Zhang, Anne Le, Sarah R. Amend, Kenneth J. Pienta
BackgroundLipid reprogramming is a known mechanism to increase the energetic demands of proliferating cancer cells to drive and support tumorigenesis and progression. Elevated lipid droplets (LDs) are a well‐known alteration of lipid reprogramming in many cancers, including prostate cancer (PCa), and are associated with high tumor aggressiveness as well as therapy resistance. The mechanism of LD accumulation
-
-
A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin‐induced apoptosis in castration‐resistant prostate cancer Prostate (IF 2.8) Pub Date : 2024-02-20 Pei‐Chen Ye, Wohn‐Jenn Leu, Tsung‐Yu Yeh, Yu‐Tung Hsu, Yi‐Chin Lin, Zi‐Yuan Wei, Yi‐Chin Chen, Yi‐Chang Chiang, Jui‐Ling Hsu, She‐Hung Chan, Lih‐Ching Hsu, Ji‐Wang Chern, Chao‐Wu Yu, Jih‐Hwa Guh
BackgroundMetastatic castration‐resistant prostate cancer (CRPC), the most refractory prostate cancer, inevitably progresses and becomes unresponsive to hormone therapy, revealing a pressing unmet need for this disease. Novel agents targeting HDAC6 and microtubule dynamics can be a potential anti‐CRPC strategy.MethodsCell proliferation was examined in CRPC PC‐3 and DU‐145 cells using sulforhodamine
-
Development of depression in patients using androgen deprivation therapy: A systemic review and meta‐analysis Prostate (IF 2.8) Pub Date : 2024-02-19 Shurjeel Uddin Qazi, Zahabia Altaf, Mariam Zafar, Muhammad Ali Tariq, Areesha Khalid, Aleesha Kaleem, Emaan Saad, Sana Qazi
BackgroundAndrogen deprivation therapy (ADT) is an effective treatment for advanced prostate cancer (PCa). Multiple studies have highlighted serious consequences this therapy poses to mental health, particularly depression. We aimed to review the incidence and association between ADT in men with PCa and the risk of depression.MethodsWe systematically searched multiple databases, including MEDLINE,
-
Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms Prostate (IF 2.8) Pub Date : 2024-02-14 Lorenzo Romano, Luigi Napolitano, Felice Crocetto, Carmine Sciorio, Marco De Sio, Agnese Miranda, Marco Romano, Kateryna Priadko
Gut microbiome is a community of microorganisms that lives in the human intestine and exerts various functions on the host, including metabolic, immunoregulatory, and control over cell proliferation. Gut microbiome alterations have been associated with various pathological conditions, such as diabetes mellitus, obesity, and cardiovascular diseases. Gut-prostate axis is explained by the association
-
Nonantibiotic strategies to decrease the postbiopsy hospitalization rates because of infectious complications after transrectal prostate biopsy Prostate (IF 2.8) Pub Date : 2024-02-14 Coşkun Bostancı
To compare the effect of biopsy needle disinfection with 10% formalin solution alone and with povidone-iodine rectal cleaning on preventing infectious complications requiring hospitalization.
-
Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990–2019: A comparable study of key nations with emerging economies Prostate (IF 2.8) Pub Date : 2024-02-08 Li-Sha Luo, Jiao Huang, Hang-Hang Luan, Sumaira Mubarik, Quliang Zhong, Xian-Tao Zeng
The study aimed to analyze epidemiology burden of male prostate cancer across the BRICS-plus, and identify potential risk factors by assessing the associations with age, period, birth cohorts and sociodemographic index (SDI).
-
Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial Prostate (IF 2.8) Pub Date : 2024-02-04 Albertas Ulys, Feliksas Jankevicus, Mindaugas Jievaltas, Raimundas Venckus, Stasys Auskalnis, Zygimantas Kardelis, Marija Barisiene, Carol M. MacLean, Steve van Os, Finn Larsen
Teverelix drug product (DP) is a novel injectable gonadotropin-releasing hormone antagonist.
-
Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors Prostate (IF 2.8) Pub Date : 2024-02-04 Juliana Arenas Hoyos, David Ruiz Londoño, Andres Gomez Hoyos, Estefania Celis Reyes, Rodolfo Varela, Julian Serrano Giraldo
The treatment and surveillance of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved since the introduction of several treatment intensification options associated with hormonal blockade and classifications based on the timing of metastatic disease presentation and disease volume. Using a hospital-based registry, we aimed to assess whether these new classifications are applicable to our
-
Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis Prostate (IF 2.8) Pub Date : 2024-01-11 Jorge Panach-Navarrete, Vannina González-Marrachelli, José Manuel Morales-Tatay, Francisco García-Morata, María Ángeles Sales-Maicas, Daniel Monleón-Salvado, José María Martínez-Jabaloyas
In this study we used nuclear magnetic resonance spectroscopy in prostate tissue to provide new data on potential biomarkers of prostate cancer in patients eligible for prostate biopsy.
-
Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) Prostate (IF 2.8) Pub Date : 2024-01-09 Dana Cavanaugh, Alfonso Urbanucci, Nihal E. Mohamed, Ashutosh K. Tewari, Mariana Figueiro, Natasha Kyprianou
Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging males, affecting 50% of men over 50 and up to 80% of men over 80 years old. Its negative impact on health-related quality of life implores further investigation into its risk factors and strategies for effective management. Although the exact molecular mechanisms underlying pathophysiological onset of BPH are poorly defined
-
Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways Prostate (IF 2.8) Pub Date : 2024-01-08 Jason A. White, Ernest T. Kaninjing, Kayode A. Adeniji, Paul Jibrin, John O. Obafunwa, Chidiebere N. Ogo, Faruk Mohammed, Ademola Popoola, Omolara A. Fatiregun, Olabode P. Oluwole, Roland J. Thorpe, Balasubramanyam Karanam, Isra Elhussin, Stefan Ambs, Wei Tang, Melissa Davis, Paz Polak, Moray J. Campbell, Kathryn R. Brignole, Solomon O. Rotimi, Windy Dean-Colomb, Folake T. Odedina, Clayton Yates
Through whole-exome sequencing of 60 formalin-fixed paraffin-embedded Nigerian (NGRn) benign prostatic hyperplasia (BPH) samples, we identified germline and somatic alterations in apoptotic pathways impacting BPH development and progression. Prostate enlargement is a common occurrence in male aging; however, this enlargement can lead to lower urinary tract symptoms that negatively impact quality of
-
Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance Prostate (IF 2.8) Pub Date : 2024-01-03 Renjie Jin, Connor M. Forbes, Nicole L. Miller, John Lafin, Douglas W. Strand, Thomas Case, Justin M. Cates, Qi Liu, Marisol Ramirez-Solano, James L. Mohler, Robert J. Matusik
The medical therapy of prostatic symptoms (MTOPS) trial randomized men with symptoms of benign prostatic hyperplasia (BPH) and followed response of treatment with a 5α-reductase inhibitor (5ARI), an alpha-adrenergic receptor antagonist (α-blocker), the combination of 5ARI and α-blocker or no medical therapy (none). Medical therapy reduced risk of clinical progression by 66% but the reasons for nonresponse
-
Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China Prostate (IF 2.8) Pub Date : 2024-01-03 Chichen Zhang, Xiang Tu, Jindong Dai, Zilong Zhang, Chenlan Shen, Qiyou Wu, Zhenhua Liu, Tianhai Lin, Shi Qiu, Lu Yang, Ling Yang, Mengni Zhang, Diming Cai, Yige Bao, Hao Zeng, Qiang Wei
Data on the utilization and effects of prebiopsy prostate multiparametric magnetic resonance imaging (mpMRI) to support its routine use in real-world setting are still scarce.
-
Diagnosis and management of neuroendocrine prostate cancer Prostate (IF 2.8) Pub Date : 2024-01-03 Ivan de Kouchkovsky, Emily Chan, Charles Schloss, Christian Poehlein, Rahul Aggarwal
Although most patients with prostate cancer (PC) respond to initial androgen deprivation therapy (ADT), castration-resistant disease invariably develops. Progression to treatment-emergent neuroendocrine PC (t-NEPC) represents a unique mechanism of resistance to androgen receptor (AR)-targeted therapy in which lineage plasticity and neuroendocrine differentiation induce a phenotypic switch from an AR-driven
-
Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy Prostate (IF 2.8) Pub Date : 2024-01-03 Ghazi Alanazi, Najah Alsubaie, Ghulam Nabi, Thomas H. Gillingwater, Abduelmenem Alashkham
Radical prostatectomy remains the main choice of treatment for prostate cancer. However, despite improvements in surgical techniques and neurovascular sparing procedures, rates of erectile dysfunction, and urinary incontinence remain variable. This is due, at least in part, to an incomplete understanding of neurovascular structures associated with the prostate. The objective of this study was to provide
-
Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy Prostate (IF 2.8) Pub Date : 2024-01-03 Yu Ozawa, Sunao Nohara, Ken Nakamura, Seiya Hattori, Yasuto Yagi, Toru Nishiyama, Atsunori Yorozu, Tetsuo Monma, Shiro Saito
After brachytherapy, fewer prostate biopsy cores at diagnosis can underestimate the pathological characteristics of prostate cancer (PCa) with lower concordance, resulting in improper treatment, particularly in patients with low-risk nonpalpable cT1c PCa. The aim of this study was to assess the relationship between the number of biopsy cores at diagnosis and long-term clinical outcomes after brachytherapy
-
Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer Prostate (IF 2.8) Pub Date : 2023-12-27 Francesco Pellegrino, Armando Stabile, Gabriele Sorce, Elio Mazzone, Donato Cannoletta, Giuseppe Ottone Cirulli, Leonardo Quarta, Riccardo Leni, Daniele Robesti, Giorgio Brembilla, Giorgio Gandaglia, Francesco De Cobelli, Francesco Montorsi, Alberto Briganti
To assess the variation of multiparametric magnetic resonance imaging (mpMRI) positive predictive value (PPV) according to each patient's risk of clinically significant prostate cancer (csPCa) based exclusively on clinical factors.
-
Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma Prostate (IF 2.8) Pub Date : 2023-12-27 Stephen Mackay, Ian O. Oduor, Tanya C. Burch, Dean A. Troyer, Oliver J. Semmes, Julius O. Nyalwidhe
Prostate-specific membrane antigen (PSMA) is a US Food and Drug Administration-approved theranostic target for prostate cancer (PCa). Although PSMA is known to be glycosylated, the composition and functional roles of its N-linked glycoforms have not been fully characterized.
-
A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia Prostate (IF 2.8) Pub Date : 2023-12-27 Kwang Suk Lee, Jeong Woo Yoo, Dae Ho Kim, Soyoung Jeon, Juyeon Yang, Byung Ha Chung, Kyo Chul Koo
It is uncertain how long combination therapy should be continued in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). We investigated the withdrawal effects of α1-adrenergic receptor blocker (AB) or 5α-reductase inhibitor (5ARI) following successful combination therapy.
-
PrLZ regulates EMT and invasion in prostate cancer via the TGF-β1/p-smad2/miR-200 family/ZEB1 axis Prostate (IF 2.8) Pub Date : 2023-12-25 Hongjun Xie, Jiaqi Chen, Zhenkun Ma, Yang Gao, Jin Zeng, Yule Chen, Zhao Yang, Shan Xu
Prostate leucine zipper (PrLZ) is a prostate-specific protein, and our previous study demonstrated that PrLZ enhances the malignant progression of prostate cancer (Pca). However, the roles of PrLZ in epithelial to mesenchymal transition (EMT) remain unknown.
-
Emotion-centered versus fact-centered medical information to alleviate pain and anxiety in prostate biopsy: A randomized trial Prostate (IF 2.8) Pub Date : 2023-12-20 Philipp Krausewitz, Helene Schmeller, Carsten Spitzer, Jörg Ellinger, Manuel Ritter, Katja Petrowski, Rupert Conrad
To test the efficacy of emotion-centered (EC) versus fact-centered (FC) written medical information for prostate biopsy to alleviate pain and anxiety in a randomized controlled trial.
-
Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4−20 ng/mL Prostate (IF 2.8) Pub Date : 2023-12-20 Hua Huang, Zihao Liu, Yuan Ma, Yuan Shao, Zhen Yang, Dengyi Duan, Yang Zhao, Simeng Wen, Jing Tian, Yang Liu, Zeyuan Wang, Dan Yue, Yong Wang
The study aimed to investigate the diagnostic accuracy of prostate health index (PHI) and apparent diffusion coefficient (ADC) values in predicting prostate cancer (PCa) and construct a nomogram for the prediction of PCa and clinically significant PCa (CSPCa) in Prostate Imaging-Reporting and Data System (PI-RADS) three lesions cohort.
-
Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors Prostate (IF 2.8) Pub Date : 2023-12-19 Mathilde Cancel, David Crottes, Dorine Bellanger, Frank Bruyère, Coralie Mousset, Michelle Pinault, Karine Mahéo, Gaëlle Fromont
Periprostatic adipose tissue (PPAT) is likely to modulate prostate cancer (PCa) progression. We analyzed the variations in the effect of PPAT on cancer cells, according to its fatty acid (FA) composition and tumor characteristics.
-
Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer Prostate (IF 2.8) Pub Date : 2023-12-19 Giuseppe R. D'Agostino, Marco Badalamenti, Sara Stefanini, Davide Baldaccini, Ciro Franzese, Lorenzo Lo Faro, Luciana Di Cristina, Veronica Vernier, Giacomo Reggiori, Marta Scorsetti
In 2016 we published a phase II study exploring safety and efficacy of Stereotactic Body Radiation Therapy (SBRT) delivered with Volumetric Modulated Arc Therapy (VMAT) and Flattening Filter Free (FFF) beams techniques in prostate cancer (PC) patients. We present herein the updated results on late toxicity and long-term survival.
-
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer Prostate (IF 2.8) Pub Date : 2023-12-18 Alexander Lukez, Elizabeth Handorf, Nancy P. Mendenhall, Randal H. Henderson, Bradley J. Stish, Brian J. Davis, Mark Hallman, Eric M. Horwitz, Neha Vapiwala, Jessica Karen Wong
We sought to characterize and compare late patient-reported outcomes (PROs) after moderately hypofractionated intensity modulated radiation therapy (IMRT) and proton beam therapy (PBT) for localized prostate cancer (PC).
-
Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer Prostate (IF 2.8) Pub Date : 2023-12-12 David Moon, J. Spencer Hauck, Xue Jiang, Holly Quang, Lingfan Xu, Fan Zhang, Xia Gao, Robert Wild, Jeffrey I. Everitt, Everardo Macias, Yiping He, Jiaoti Huang
Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and has limited treatment options. Our previous study identified glutamine metabolism to be critical for CRPC growth. The glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) blocks both carbon and nitrogen
-
4-Octyl itaconate alleviates experimental autoimmune prostatitis by inhibiting the NLRP3 inflammasome-induced pyroptosis through activating Nrf2/HO-1 pathway Prostate (IF 2.8) Pub Date : 2023-12-10 Xiaohu Zhao, Rui Feng, Juan Chen, Qing Jiang, Xiaoliang Hua, Chaozhao Liang
Chronic prostatitis demonstrates a prevalence rate of nearly 5%–10% among young and middle-aged individuals, significantly affecting their daily lives. Researchers have obtained significant outcomes investigating the anti-inflammatory properties of itaconic acid (IA) and its derivative, 4-Octyl itaconate (4-OI), against diverse chronic inflammatory disorders, such as osteoarthritis and airway inflammation
-
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer Prostate (IF 2.8) Pub Date : 2023-12-01 Praful Ravi, Lucia Kwak, Wout Devlies, Wanling Xie, Fallon Chipidza, Xiaoyu Yang, Glenn Bubley, Irving Kaplan, Adam S. Kibel, Paul Nguyen, Mary-Ellen Taplin
We sought to describe patterns of delivery of adjuvant (aRT) and salvage RT (sRT) in patients who underwent RP after receiving neoadjuvant androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC).
-
Maternal diet during gestation affect prostatic tissue component in SHR/Izm offspring Prostate (IF 2.8) Pub Date : 2023-11-30 Kosuke Shibamori, Yuki Kyoda, Tetsuya Shindo, Kohei Hashimoto, Ko Kobayashi, Toshiaki Tanaka, Hiromu Suzuki, Naoya Masumori
Numerous studies have investigated the associations between maternal nutritional status and various diseases, with the underlying mechanism often attributed to epigenetic changes. However, limited research has been conducted on the relationship between maternal nutrition and benign prostatic hyperplasia (BPH). In this study, we aimed to explore the potential association between maternal nutrition and
-
Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population Prostate (IF 2.8) Pub Date : 2023-11-15 Zainab Al Shareef, Rula Al-Shahrabi, Fatemeh Saheb Sharif-Askari, Amna AlDhmanie, Younis Alshamsi, Abdulqadir Al Zarooni, Rabah Al Mahmoud, Sameh S. M. Soliman, Rabih Halwani, Riyad Bendardaf
Prostate cancer (PCa) is a prevalent disease worldwide. However, the incidence and patient-specific risk factors of PCa in the Middle East, specifically in the United Arab Emirates, have not been previously reported.
-
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness Prostate (IF 2.8) Pub Date : 2023-11-14 Channing J. Paller, Pedro C. Barata, Justin Lorentz, Leonard J. Appleman, Andrew J. Armstrong, Tiffani A. DeMarco, Robert Dreicer, Jo Ann B. Elrod, Mark Fleming, Christopher George, Elisabeth I. Heath, Maha H. A. Hussain, Shifeng Mao, Rana R. McKay, Alicia K. Morgans, Matthew Orton, Roberto Pili, Elyn Riedel, Biren Saraiya, Joelle Sigmond, Alexandra Sokolova, Walter M. Stadler, Christina Tran, Natalie
Recently approved treatments and updates to genetic testing recommendations for prostate cancer have created a need for correlated analyses of patient outcomes data via germline genetic mutation status. Genetic registries address these gaps by identifying candidates for recently approved targeted treatments, expanding clinical trial data examining specific gene mutations, and understanding effects
-
Urinary microbiota is associated to clinicopathological features in benign prostatic hyperplasia Prostate (IF 2.8) Pub Date : 2023-11-13 Antonio C. H. Mariotti, Vitor Heidrich, Lilian T. Inoue, Elisangela M. Coser, Ernande X. dos Santos, Hugo D. B. dos Santos, Carolina B. T. Rocha, Paula F. Asprino, Fabiana Bettoni, Diogo A. Bastos, Denis L. F. Jardim, Anamaria A. Camargo, Marco A. Arap
The urinary microbiota of patients with benign prostatic hyperplasia (BPH) has been associated with lower urinary tract symptoms (LUTS), however, little is known about urinary microbiota correlations with clinicopathological parameters associated with BPH. Here, we investigate associations between the urinary microbiota and clinical parameters of patients with BPH undergoing surgery.
-
Association of plasma NRP2 and VEGF-C levels with prostate cancer disease severity Prostate (IF 2.8) Pub Date : 2023-11-09 Sarah A. Mullen, Dipanwita Das, Negin Ziamiavaghi, Robin High, Kaustubh Datta, Benjamin A. Teply
Neuropilin 2 (NRP2) expression in tissue is an independent prognostic factor for aggressive prostate cancer. Since the NRP2 pathway activation is thought to occur in part through secondary resistance, quantification of NRP2 in initial tissue biopsy specimens collected at diagnosis may have limited utility in identifying patients at highest risk for morbidity and mortality. Given that metastatic tissue
-
The 29th Annual Prostate Cancer Foundation Scientific Retreat Report Prostate (IF 2.8) Pub Date : 2023-11-01 Andrea K. Miyahira, Howard R. Soule
The 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat was held from October 27 to 29, 2022, at the Omni La Costa Resort in Carlsbad, CA. This was the first-ever hybrid PCF Retreat.
-
Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide Prostate (IF 2.8) Pub Date : 2023-11-01 Srinivas Govindan, Nina Cheranda, Forest Riekhof, Suhong Luo, Martin W. Schoen
Abiraterone acetate and enzalutamide are two common therapies for metastatic castration-resistant prostate cancer (mCRPC) that have shown improved overall survival (OS). The drugs have different mechanisms of action with limited comparative trials to evaluate treatment in patients with comorbidities such as obesity and diabetes. This is important since abiraterone requires the co-administration of
-
Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis Prostate (IF 2.8) Pub Date : 2023-10-31 Huajie Di, Yi Wen
Previous reports have shown a potential causal impact of vasectomy on prostate cancer (PCa). The objective of this study was to investigate the association between vasectomy and PCa, while evaluating the influence of confounding factors such as prostate-specific antigen (PSA) screening and body mass index (BMI).
-
Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer Prostate (IF 2.8) Pub Date : 2023-10-31 Omar Awad Alsaidan, Emmanuel Onobun, Chenming Ye, Lei Lou, Zanna Beharry, Zhong-Ru Xie, Iryna Lebedyeva, David Crich, Houjian Cai
Even though prostate cancer (PCa) patients initially respond to androgen deprivation therapy, some will eventually develop castration resistant prostate cancer (CRPC). Androgen receptor (AR) mediated cell signaling is a major driver in the progression of CRPC while only a fraction of PCa becomes AR negative. This study aimed to understand the regulation of AR levels by N-myristoyltransferase in PCa
-
Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial Prostate (IF 2.8) Pub Date : 2023-10-30 Rafael Sanchez-Salas, Rafael Tourinho-Barbosa, Arjun Sivaraman, Rafael Castilho Borges, Luigi Candela, Nathalie Cathala, Annick Mombet, Giancarlo Marra, Lara Rodriguez Sanchez, Chahrazad Bey Boumezrag, Camille Lanz, Petr Macek, Fernando Korkes, Xavier Cathelineau
Urinary incontinence (UI) can negatively impact quality of life (QoL) after robot-assisted radical prostatectomy (RARP). Pelvic floor muscle training (PFMT) and duloxetine are used to manage post-RARP UI, but their efficacy remains uncertain. We aimed to investigate the efficacy of PFMT and duloxetine in promoting urinary continence recovery (UCR) after RARP.
-
Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy Prostate (IF 2.8) Pub Date : 2023-10-30 Wei Fu, Lei Xu, Yingwen Chen, Zezheng Zhang, Shuchao Chen, Qixin Li, Xujun You
As the second most common cancer in men and the leading cause of cancer-related death, prostate cancer (PCa) could potentially be treated by inducing ferroptosis. In this study, we aimed to investigate whether luteolin could induce ferroptosis in PCa cells through the transcription Factor EB (TFEB).
-
Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis Prostate (IF 2.8) Pub Date : 2023-10-29 Ahmed M. Mahmoud, Daniel S. Childs, Mohamed E. Ahmed, A. Tuba Kendi, Geoffrey B. Johnson, Jacob J. Orme, Bradley J. Stish, Ryan M. Phillips, Sean S. Park, Brian J. Davis, Jack R. Andrews, Eugene D. Kwon
Prostate cancer (PCa) parenchymal brain metastases are uncommon and troubling observations in the course of the disease. Our study aims to evaluate the prevalence of brain metastases among PCa patients while reporting various therapeutic modalities, clinical features, and oncological outcomes.
-
The association between several serum micronutrients and benign prostatic hyperplasia: Results from NHANES 2003−2006 Prostate (IF 2.8) Pub Date : 2023-10-29 Hang Zhou, Mingming Xu, Yang Pan, Shangren Wang, Zhunan Xu, Li Liu, Xiaoqiang Liu
Benign prostatic hyperplasia (BPH) is a common condition that affects the quality of life of older men. Specific micronutrients, including retinol, retinyl esters, carotenoids, vitamin E, and vitamin C, have antioxidant and anti-inflammatory properties. However, the correlation between serum concentrations of these micronutrients and BPH is unclear.
-
Biological role of fructose in the male reproductive system: Potential implications for prostate cancer Prostate (IF 2.8) Pub Date : 2023-10-27 Carolina E. Echeverría, Vanessa I. Oyarzún, Andrés López-Cortés, Jorge Cancino, Paula C. Sotomayor, Marcus D. Goncalves, Alejandro S. Godoy
Over the last 20 years, fructose has gradually emerged as a potential metabolic substrate capable of promoting the growth and progression of various cancers, including prostate cancer (PCa). The biological and molecular mechanisms that underlie the effects of fructose on cancer are beginning to be elucidated.
-
Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers Prostate (IF 2.8) Pub Date : 2023-10-25 Hsin-pei Hu, Gregory Anagnostopoulos, Mohammad Gouran-Savadkoohi, Ian Dayes, Adrian Ishkanian, Abhirami Hallock, Himanshu Lukka, Kimmen Quan, Kara Schnarr, David Cuthbert, Mira Goldberg, Yi Meng Chang, Theodoros Tsakiridis
Advantages of using stereotactic body radiation therapy to treat prostate cancer include short treatment times, decreased costs, and limited toxicity. Randomized trial outcomes comparing 5-fraction stereotactic body radiation therapy to conventionally fractionated radiotherapy or hypo-fractionated radiation therapy are pending.
-
The activated complement pathway in the fibrous process of benign prostatic hyperplasia Prostate (IF 2.8) Pub Date : 2023-10-25 Junya Hata, Kanako Matsuoka, Hidenori Akaihata, Satoru Meguro, Ruriko Honda-Takinami, Akifumi Onagi, Tomoyuki Koguchi, Yuichi Sato, Masao Kataoka, Motohide Uemura, Yoshiyuki Kojima
To elucidate the changes in activated complement pathway in the fibrous process of benign prostatic hyperplasia (BPH), we analyzed the correlation between complement component expression and histological types of fibrosis using human BPH tissue.
-
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate Prostate (IF 2.8) Pub Date : 2023-10-17 Onur Ertunc, Erica Smearman, Qizhi Zheng, Jessica L. Hicks, Jacqueline A. Brosnan-Cashman, Tracy Jones, Carolina Gomes-Alexandre, Levent Trabzonlu, Alan K. Meeker, Angelo M. De Marzo, Christopher M. Heaphy
Telomeres are terminal chromosomal elements that are essential for the maintenance of genomic integrity. The measurement of telomere content provides useful diagnostic and prognostic information, and fluorescent methods have been developed for this purpose. However, fluorescent-based tissue assays are cumbersome for investigators to undertake, both in research and clinical settings.
-
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer Prostate (IF 2.8) Pub Date : 2023-10-16 Aaron P. Mitchell, Sonia Persaud, Paul Palyca, Andrew Salner, Azeez Farooki, Jamie S. Ostroff, Michael J. Morris, Susan Chimonas
Guidelines recommend bone-modifying agents (BMAs) for patients with castrate-resistant prostate cancer (CRPC) and bone metastasis, but not for castrate-sensitive prostate cancer (CSPC). Physicians beliefs and practices regarding BMA therapy are poorly understood.
-
Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes Prostate (IF 2.8) Pub Date : 2023-10-16 Nava Siegelmann-Danieli, Victoria Neiman, Avital Bareket-Samish, Racheli Berger, Asaf Peretz, Hillel Alapi, Erez Tsur, Tal Patalon, Daniella Beller, Galit Rimler, Gabriel Chodick, Mordechai Shohat
Whole exome sequencing (WES) furthered our understanding of various tumors. We assessed the occurrence of germline likely pathogenic/pathogenic (LP/P) variants, disease features, and clinical outcomes in early-onset prostate cancer.
-
Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ Prostate (IF 2.8) Pub Date : 2023-10-15 Raphaela dos Santos Menezes, Maria Cristina Dornas, Carlos Frederico Ferreira Campos, Daniela Bouzas Rodeiro, Fabricio Borges Carrerette, Romulo Vianna Oliveira, Brenda Amaral de Souza, Gabriele Alves de Souza Carvalho, Ingrid Alexandre de Abreu Brito, Dayse Aparecida Silva, Ronaldo Damião, Luís Cristóvão Porto
Prostate cancer (PCa) is the leading cause of death among men in 48 countries. Genetic alterations play a significant role in PCa carcinogenesis. For the hypothesis of this research, five unique polymorphisms (SNP) were investigated in different genes that showed to be associated in different ways with PCa: rs4430796, rs2735839, rs4792311, rs12329760, and rs28931588, respectively for the genes HNF1B
-
Microultrasound in the detection of the index lesion in prostate cancer Prostate (IF 2.8) Pub Date : 2023-10-12 Adriana M. Pedraza, Raghav Gupta, David Musheyev, Tanisha Pino, Akash Shah, Rachel Brody, Vinayak Wagaskar, Basil Kaufmann, Michael A. Gorin, Mani Menon, Ashutosh Tewari
The natural progression of prostate cancer is primarily driven by an index lesion (IL). Studies have shown that different metastases within the same patient arise from a single precursor cell. Therefore, our aim is to assess the effectiveness of transrectal microultrasound (MUS) in comparison to multiparametric magnetic resonance imaging (mpMRI) for detecting the IL in prostate cancer. We used quarter-mount
-
Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer Prostate (IF 2.8) Pub Date : 2023-10-12 Lili Wang, Chen Lyu, Birgit Stadlbauer, Alexander Buchner, Elfriede Nößner, Heike Pohla
Cancer stem cells (CSCs) are a small subpopulation of tumor cells with the capability of self-renewal and drug resistance, leading to tumor progression and disease relapse. Our study aimed to investigate the antitumor effect of berbamine, extracted from berberis amurensis, on prostate CSCs.